Modern natural products drug discovery and its relevance to biodiversity conservation
- PMID: 21138324
- PMCID: PMC3061248
- DOI: 10.1021/np100550t
Modern natural products drug discovery and its relevance to biodiversity conservation
Abstract
Natural products continue to provide a diverse and unique source of bioactive lead compounds for drug discovery, but maintaining their continued eminence as source compounds is challenging in the face of the changing face of the pharmaceutical industry and the changing nature of biodiversity prospecting brought about by the Convention on Biological Diversity. This review provides an overview of some of these challenges and suggests ways in which they can be addressed so that natural products research can remain a viable and productive route to drug discovery. Results from International Cooperative Biodiversity Groups (ICBGs) working in Madagascar, Panama, and Suriname are used as examples of what can be achieved when biodiversity conservation is linked to drug discovery.
Figures














Similar articles
-
Biodiversity conservation and drug discovery: Can they be combined? The Suriname and Madagascar experiences.Pharm Biol. 2009 Aug 1;47(8):809-823. doi: 10.1080/13880200902988629. Pharm Biol. 2009. PMID: 20161050 Free PMC article.
-
A natural love of natural products.J Org Chem. 2008 Jun 6;73(11):3975-84. doi: 10.1021/jo800239a. Epub 2008 May 7. J Org Chem. 2008. PMID: 18459734 Free PMC article.
-
The UIC ICBG (University of Illinois at Chicago International Cooperative Biodiversity Group) Memorandum of Agreement: a model of benefit-sharing arrangement in natural products drug discovery and development.J Nat Prod. 2004 Feb;67(2):294-9. doi: 10.1021/np0304363. J Nat Prod. 2004. PMID: 14987071 Review.
-
Biodiversity as a source of anticancer drugs.Curr Drug Targets. 2006 Mar;7(3):265-77. doi: 10.2174/138945006776054942. Curr Drug Targets. 2006. PMID: 16515527 Review.
-
Cheminformatic characterization of natural products from Panama.Mol Divers. 2017 Nov;21(4):779-789. doi: 10.1007/s11030-017-9781-4. Epub 2017 Aug 22. Mol Divers. 2017. PMID: 28831697
Cited by
-
Jejuketomycins A and B, polyketide glycosides with cancer cell migration inhibitory activity from Streptomyces sp. KCB15JA151.RSC Adv. 2022 Aug 10;12(35):22360-22366. doi: 10.1039/d2ra04039e. eCollection 2022 Aug 10. RSC Adv. 2022. PMID: 36105948 Free PMC article.
-
MAP: model-based analysis of proteomic data to detect proteins with significant abundance changes.Cell Discov. 2019 Aug 13;5:40. doi: 10.1038/s41421-019-0107-9. eCollection 2019. Cell Discov. 2019. PMID: 31636953 Free PMC article.
-
Role of curcumin in regulating p53 in breast cancer: an overview of the mechanism of action.Breast Cancer (Dove Med Press). 2018 Nov 29;10:207-217. doi: 10.2147/BCTT.S167812. eCollection 2018. Breast Cancer (Dove Med Press). 2018. PMID: 30568488 Free PMC article. Review.
-
Motifs in Natural Products as Useful Scaffolds to Obtain Novel Benzo[d]imidazole-Based Cannabinoid Type 2 (CB2) Receptor Agonists.Int J Mol Sci. 2023 Jun 30;24(13):10918. doi: 10.3390/ijms241310918. Int J Mol Sci. 2023. PMID: 37446093 Free PMC article.
-
Withaferin A Inhibits STAT3 and Induces Tumor Cell Death in Neuroblastoma and Multiple Myeloma.Biochem Insights. 2014 Nov 9;7:1-13. doi: 10.4137/BCI.S18863. eCollection 2014. Biochem Insights. 2014. PMID: 25452693 Free PMC article.
References
-
- Newman DJ, Cragg GM. J Nat Prod. 2007;70:461–477. - PubMed
-
- McChesney JD, Venkataraman SK, Henri JT. Phytochemistry. 2007;68:2015–2022. - PubMed
-
- Kingston DGI, Newman DJ. Current Opin Drug Disc Devel. 2002;5:304–316. - PubMed
-
- Butler MS. Nat Prod Rep. 2008;25:475–516. - PubMed
-
- Baker DD, Chu M, Oza U, Rajgarhia V. Nat Prod Rep. 2007;24:1225–1244. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources